-
2023.01.23
J-Pharma presented Japanese Phase II Trial of Nanvuranlat at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2023 Nanvuranlat met primary endpoint in Japanese Phase II Trial for patients with refractory, advanced biliary tract cancers
-
What's new
- J-Pharma Presented the latest findings on LAT1 inhibitor NANVURANLAT (development code: JPH203) at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI2024) 2024/01/22
- J-Pharma Presenting at the J.P. Morgan Healthcare Conference 2024 for the Fourth Consecutive Year 2024/01/12
- Announcement of presentation at the J.P. Morgan Healthcare Conference 2024 2023/12/13
- Financing total 2.4 billion yen completed through a third-party allotment of new shares (Round E) 2023/10/05
- J-Pharma Receives Award from the National Multiple Sclerosis Society to Develop JPH034 as a Potential Treatment for Progressive Multiple Sclerosis 2023/10/05
-
Monthly
- 2024.01 (2)
- 2023.12 (1)
- 2023.10 (3)
- 2023.06 (3)
- 2023.05 (1)
- 2023.04 (1)
- 2023.03 (2)
- 2023.01 (3)
- 2022.12 (2)
- 2022.05 (1)
- 2022.04 (1)
- 2022.01 (1)
- 2021.11 (1)
- 2021.07 (1)
- 2021.03 (2)
- 2021.02 (1)
- 2021.01 (2)
- 2020.07 (1)
- 2020.06 (1)
- 2019.12 (1)
- 2019.04 (1)
- 2018.12 (1)
- 2018.07 (1)
- 2018.05 (1)
- 2018.03 (1)
- 2018.01 (1)
- 2017.09 (1)
- 2016.05 (1)
- 2015.11 (1)
- 2015.04 (1)
- 2015.02 (1)